DAFNA Capital Management »

Elevation Oncology shares owned by DAFNA Capital Management

Quarter-by-quarter ownership of Elevation Oncology (ELEV) shares owned by DAFNA Capital Management from 13F filings

Historical chart of DAFNA Capital Management investment in Elevation Oncology

Tip: Access up to 7 years of quarterly data

All positions including Elevation Oncology held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Elevation Oncology by DAFNA Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $242k 450k 0.54
2023-09-30 $298k 450k 0.66
2023-06-30 $684k 450k 1.52

More positions owned by DAFNA Capital Management

Spdr S&p Biotech Etf Etf (XBI)
Cytokinetics Com New (CYTK)
Stereotaxis Com New (STXS)
Ideaya Biosciences (IDYA)
Syndax Pharmaceuticals (SNDX)
Ascendis Pharma A/s Sponsored Adr (ASND)
Karuna Therapeutics Ord
Revolution Medicines (RVMD)
Ishares Nasdaq Biotech Indx Etf (IBB)
Xenon Pharmaceuticals (XENE)
Merus N V (MRUS)
Blueprint Medicines (BPMC)
Day One Biopharmaceuticals I (DAWN)
Neurocrine Biosciences (NBIX)
Dex (DXCM)

View all positions for DAFNA Capital Management

Top funds holding Elevation Oncology

Tang Capital Management
Millennium Management
venBio Partners
Aisling Capital Management
Qiming U.S. Ventures Management
BVF
OrbiMed Advisors
Ikarian Capital
Vanguard Group
Sphera Funds Management
Citadel Advisors
Hudson Bay Capital Management
DAFNA Capital Management
Two Sigma Investments
Bank of America Corporation

View all funds holding Elevation Oncology